Guardant Health GH
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Guardant Health (GH) Business Model and Operations Summary
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Key Insights
Guardant Health (GH) Core Market Data and Business Metrics
Latest Closing Price
$42.47Market Cap
$5.25 BillionPrice-Earnings Ratio
-11.93Total Outstanding Shares
123.42 Million SharesTotal Employees
2,021Dividend
No dividendIPO Date
October 4, 2018SIC Description
Services-medical LaboratoriesPrimary Exchange
NASDAQHeadquarters
3100 Hanover Street, Palo Alto, CA, 94304
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-261.31 Million |
| Net Cash Flow From Investing Activities | $-261.31 Million |
| Net Cash Flow From Financing Activities, Continuing | $-996,000 |
| Net Cash Flow From Operating Activities | $-239.86 Million |
| Net Cash Flow | $-502.16 Million |
| Net Cash Flow From Financing Activities | $-996,000 |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $122.75 Million |
| Income/Loss From Continuing Operations After Tax | $-436.37 Million |
| Revenues | $739.02 Million |
| Income Tax Expense/Benefit, Current | $997,000 |
| Research and Development | $347.75 Million |
| Diluted Average Shares | $122.75 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-437.90 Million |
| Other Comprehensive Income/Loss | $-1.53 Million |
| Comprehensive Income/Loss | $-437.90 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $225.58 Million |
| Fixed Assets | $136.81 Million |
| Noncurrent Liabilities | $1.40 Billion |
| Current Assets | $1.06 Billion |
| Equity Attributable To Parent | $-139.65 Million |
| Other Current Liabilities | $187.03 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||